
Prifemilast Outperforms Apremilast in Phase 3 Psoriasis Trial
In a head-to-head Phase 3 trial, the oral PDE4B inhibitor prifemilast nearly doubled the PASI 75 response rate compared to apremilast in patients with moderate-to-severe plaque psoriasis. These results, presented at the 2026 Fall Clinical Dermatology Conference, position the drug as a potential best-in-class treatment for immune-mediated inflammatory diseases.






















